ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Apr 25, 2026, 15:08Lakmali Silva: Just Back from a Truly Energising Days in the UNC 12th Symposium on Hemostasis
-
Apr 25, 2026, 15:08Peripheral Blood Smear (PBS) Under the Microscope: Bridging Morphology and Hematology
-
Apr 25, 2026, 15:06Pushpendra Dwivedi: Blood Availability as One of Those Silent Problems No One Notices, Until It’s Too Late
-
Apr 25, 2026, 15:05Faheema Hasan: Chronic Methemoglobinemia Causing Longstanding Tissue Hypoxia and Secondary Erythrocytosis
-
Apr 25, 2026, 15:04Walk for Victory Is Coming to a Community Near You in the Weeks Ahead – The Marfan Foundation
-
Apr 25, 2026, 14:58David McIntosh: Reminding That Relph the Realism Elephant Will Be on Duty Throughout
-
Apr 25, 2026, 11:44Ruiming Li: Why the COMBO Plus form is a Masterclass in Vascular Repair
-
Apr 25, 2026, 11:19Nathan Connell: Bleeding Risk Is Not Limited to Delivery
-
Apr 25, 2026, 11:14Rashad Mohamed: What Does ‘Capping’ Mean in Anticoagulant Dosing?